VolitionRx joins France’s DETECSEPS clinical study using Nu.Q NETs biomarker for early sepsis detection - VNRX News | RalliesVolitionRx joins France’s DETECSEPS clinical study using Nu.Q NETs biomarker for early sepsis detection
V
VNRX• France-based sepsis study to evaluate Nu.Q NETs
- VolitionRx launched the DETECSEPS program in France to evaluate early sepsis detection using its Nu.Q NETs blood biomarker.
- No clinical results have been presented; the project will generate real-world evidence on emergency-department triage for suspected infections.
- The French government-backed consortium is funded at EUR 6.3 million, positioning the test for potential broader clinical adoption if validated.
- IDS France will supply the IDS i10 automated analyzer to run the assay, supporting rapid hospital workflow integration.
JEF
•
